Information;Judgment — ECLI:EU:T:2024:770
Date: 2024-11-06
Language of the case: English
Court formation: Third Chamber
Subject matter: Trade marks;Intellectual, industrial and commercial property
Procedure: Action for annulment - successful
Origin: Germany

Judgment of the General Court of 6 November 2024 – Stada Arzneimittel AG v EUIPO – Bioiberica (DAOgest) (Case T-396/23) 1 (EU trade mark – Opposition proceedings – Application for EU word mark DAOgest – Earlier EU word mark DAOSIN – Relative ground for refusal – Likelihood of confusion – Article 8(1)(b) of Regulation (EU) 2017/1001) Language of the case: English Parties Applicant: Stada Arzneimittel AG (Bad Vilbel, Germany) (represented by: J.-C. Plate, R. Kaase and K. Rachlitz, lawyers) Defendant: European Union Intellectual Property Office (represented by: D. Stoyanova-Valchanova and V. Ruzek, acting as Agents) Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Bioiberica, SAU (Palafolls, Spain) (represented by: E. Sugrañes Coca, lawyer) Re: By its action under Article 263 TFEU, the applicant seeks the annulment of the decision of the Second Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 25 April 2023 (Case R 1384/2022-2). Operative part of the judgment The Court: 1. Annuls the decision of the Second Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 25 April 2023 (Case R 1384/2022-2); 2. Orders EUIPO to bear its own costs and to pay those incurred by Stada Arzneimittel AG; 3. Orders Bioiberica, SAU to bear its own costs. ____________ 1 OJ C 314, 4.9.2023.